SUSTAIN For PAIN
SUSTAIN For PAIN: Subcostal UltraSound guided Transversus Abdominis plane INfusions for Pain relief of Abdominal INcisions
Western Hospital
80 participants
Feb 1, 2011
Interventional
Conditions
Summary
To evaluate whether local anaesthetic running via a catheter in the abdominal wall improves analgesia following abdominal surgery
Eligibility
Inclusion Criteria3
- Patients age 18 years or over.
- Elective or semi-elective surgery requiring a mid-line abdominal incision.
- Planned intraoperative Transversus Abdominis Plane blocks and postoperative morphine patient controlled analgesia.
Exclusion Criteria24
- Plan for epidural and/or spinal analgesia.
- Surgeon or anaesthetist refusal to placement of catheters.
- Inability to communicate in English due to a language barrier, cognitive deficit or intellectual disability.
- Inability of patient to use patient controlled analgesia (PCA) pump postoperatively or to understand visual analogue pain score.
- Patients flagged for postoperative ventilation.
- Asthma if exacerbated by non-steroidal anti-inflammatory drugs (NSAIDs) or asthma if a patient has never taken a NSAID.
- Acute abdomen, with clinical signs of abdominal peritonism.
- Septicaemia involving positive bacterial blood cultures.
- Localised infection at the site of proposed needle insertion.
- Opioid tolerant patients, i.e. any of the following:
- Patient taking an average of 8 Panadeine Forte tablets per day for a greater than one week.
- Patients taking greater than 40 mg oxycodone per day for greater than one week.
- Patients receiving 20 mg morphine parenterally per day for greater than one week.
- Patients on a fentanyl patch of dose greater than 12.5 mcg/hour for greater than one week.
- Any patient receiving buprenorphine.
- Any patient receiving methadone.
- Any patient receiving naltrexone or naloxone as part of an opioid abstinence program.
- Any history of injected or inhaled illicit drug use in the previous six months.
- A clinical history of chronic pain, where patients may benefit from early commencement of ketamine.
- Renal impairment with creatinine clearance less than 60 mL/min.
- Severe hepatic impairment (Child-Pugh score greater than or equal to 10).
- Patients with unstable or uncontrolled epilepsy.
- Allergy or contraindication to morphine, ropivacaine, tramadol, parocoxib, sulphonamides or paracetamol.
- Patients on ketaconazole, fluconazole, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), serotonin noradradrenaline reuptake inhibitors (SNRIs), tricyclic anti-depressents, carbemazepine, quinidine, antipsychotics, zidovudine or warfarin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ropivacaine Transversus Abdominis Plane infusion at a rate of 0.1ml/kg/hr bilaterally up to a maximum of 7ml/hr bilaterally via transversus abdominis plane catheter for 48 hours. The infusion rate will be rounded down to the nearest integer (e.g. a 68 kg patient will receive an infusion rate of 6 ml/hr bilaterally).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000246088